More stories
Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning
In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of...
Dylan Beynon – Mindbloom – At Home Ketamine
PT welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares...
Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study
British psychedelic drug developer Beckley Psytech has shared topline data from a Phase 2b study of its lead candidate, intranasal 5-MeO-DMT (BPL-003), in treatment-resistant...
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans
Psychedelic Alpha’s Josh Hardman sat down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline...
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model
This morning, executives from Beckley Psytech and atai Life Sciences hosted a conference call to discuss the topline results from their Phase 2b study...
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout
This is the second of a two-part series that looks at how people are reacting to Compass Pathways’ first readout from its Phase 3...
It’s Time to Push Back: Meta’s War on Psychedelic Voices
META is doing real damage to the psychedelic ecosystem.Shadowbans. Post removals. Account suspensions. Entire orgs—especially nonprofits—shut out of digital visibility with no explanation and...
Victoria Litman – The Future of Psychedelic Regulation Is Local
In this episode, we sit down with Victoria Litman, M.Div., J.D., LL.M., to discuss why the future of psychedelic access in the United States...
Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in...
We returned from Psychedelic Science 2025 to a very busy week, not least due to Compass Pathways’ first Phase 3 readout (read our piece...
Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results
It’s been two days since Compass Pathways provided a first look at data from its Phase 3 program, by way of a limited readout...
Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
This morning, Compass Pathways shared a readout from the first of two Phase 3 trials investigating its synthetic psilocybin candidate, COMP360, in treatment-resistant depression...
PS 25 Morning Show – Day Three
Joe Moore and Anne Philippi (New Health Club) are hosts of the PS25 Morning Show! This one features Cesar Marin, AnneClaire Stapleton, Dennis Walker,...
